Taspase1 Functions As a Non-oncogene Addiction Protease That Coordinates Cancer Cell Proliferation and Apoptosis

Overview

Journal Cancer Res

Specialty Oncology

Date 2010 Jun 3

PMID 20516119

Citations 22

Authors

David Y Chen

Han Liu

Shugaku Takeda

Ho-Chou Tu

Satoru Sasagawa

Brian A Van Tine

Dongsi Lu

Emily H-Y Cheng

James J-D Hsieh

Affiliations

Soon will be listed here.

Abstract

Taspase1, the mixed lineage leukemia and TFIIAalpha-beta cleaving protease, enables cell proliferation and permits oncogenic initiation. Here, we show its critical role in cancer maintenance and thus offer a new anticancer target. Taspase1 is overexpressed in primary human cancers, and deficiency of Taspase1 in cancer cells not only disrupts proliferation but also enhances apoptosis. Mechanistically, loss of Taspase1 induces the levels of CDK inhibitors (CDKI: p16, p21, and p27) and reduces the level of antiapoptotic MCL-1. Therapeutically, deficiency of Taspase1 synergizes with chemotherapeutic agents and ABT-737, an inhibitor of BCL-2/BCL-X(L), to kill cancer cells. Taspase1 alone or in conjunction with MYC, RAS, or E1A fails to transform NIH/3T3 cells or primary mouse embryonic fibroblasts, respectively, but plays critical roles in cancer initiation and maintenance. Therefore, Taspase1 is better classified as a "non-oncogene addiction" protease, the inhibition of which may offer a novel anticancer therapeutic strategy. The reliance of oncogenes on subordinate non-oncogenes during tumorigenesis underscores the non-oncogene addiction hypothesis in which a large class of non-oncogenes functions to maintain cancer phenotypes and presents attractive anticancer therapeutic targets. The emergence of successful cancer therapeutics targeting non-oncogenes to which cancers are addicted supports the future development and potential application of small-molecule Taspase1 inhibitors for cancer therapy.

Citing Articles

Taspase1 Facilitates Topoisomerase IIβ-Mediated DNA Double-Strand Breaks Driving Estrogen-Induced Transcription.

Oelschlager L, Stahl P, Kaschani F, Stauber R, Knauer S, Hensel A Cells. 2023; 12(3).

PMID: 36766705 PMC: 9913075. DOI: 10.3390/cells12030363.

Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand.

Hoing A, Struth R, Beuck C, Rafieiolhosseini N, Hoffmann D, Stauber R RSC Adv. 2022; 12(53):34176-34184.

PMID: 36545626 PMC: 9709806. DOI: 10.1039/d2ra06019a.

Closantel is an allosteric inhibitor of human Taspase1.

Luciano V, Proschak E, Langer J, Knapp S, Heering J, Marschalek R iScience. 2021; 24(12):103524.

PMID: 34934933 PMC: 8661544. DOI: 10.1016/j.isci.2021.103524.

A Bivalent Supramolecular GCP Ligand Enables Blocking of the Taspase1/Importin α Interaction.

Hoing A, Zimmermann A, Moews L, Killa M, Heimann M, Hensel A ChemMedChem. 2021; 17(1):e202100640.

PMID: 34623765 PMC: 9298320. DOI: 10.1002/cmdc.202100640.

TASP1 Promotes Proliferation and Migration in Gastric Cancer via EMT and AKT/P-AKT Pathway.

Wan X, Zhou X, Du Y, Shen H, Yang Z, Ding Y J Immunol Res. 2021; 2021:5521325.

PMID: 34012990 PMC: 8105097. DOI: 10.1155/2021/5521325.

References

Chen L, Willis S, Wei A, Smith B, Fletcher J, Hinds M . Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005; 17(3):393-403. DOI: 10.1016/j.molcel.2004.12.030. View

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

Loonstra A, Vooijs M, Beverloo H, Allak B, van Drunen E, Kanaar R . Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc Natl Acad Sci U S A. 2001; 98(16):9209-14. PMC: 55399. DOI: 10.1073/pnas.161269798. View

van Delft M, Wei A, Mason K, Vandenberg C, Chen L, Czabotar P . The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006; 10(5):389-99. PMC: 2953559. DOI: 10.1016/j.ccr.2006.08.027. View

Lowe S, Cepero E, Evan G . Intrinsic tumour suppression. Nature. 2004; 432(7015):307-15. DOI: 10.1038/nature03098. View

Liu H, Peng H, Cheng Y, Yuan H, Yang-Yen H . Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol Cell Biol. 2005; 25(8):3117-26. PMC: 1069602. DOI: 10.1128/MCB.25.8.3117-3126.2005. View

Vogelstein B, Kinzler K . Cancer genes and the pathways they control. Nat Med. 2004; 10(8):789-99. DOI: 10.1038/nm1087. View

Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A . BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007; 12(2):171-85. DOI: 10.1016/j.ccr.2007.07.001. View

Kim H, Tu H, Ren D, Takeuchi O, Jeffers J, Zambetti G . Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell. 2009; 36(3):487-99. PMC: 3163439. DOI: 10.1016/j.molcel.2009.09.030. View

10.

Lee J, Chen D, Yang Z, Ramos A, Hsieh J, Bogyo M . Design, syntheses, and evaluation of Taspase1 inhibitors. Bioorg Med Chem Lett. 2009; 19(17):5086-90. PMC: 3513416. DOI: 10.1016/j.bmcl.2009.07.045. View

11.

Ding Q, He X, Hsu J, Xia W, Chen C, Li L . Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol. 2007; 27(11):4006-17. PMC: 1900029. DOI: 10.1128/MCB.00620-06. View

12.

Tu H, Ren D, Wang G, Chen D, Westergard T, Kim H . The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage. Proc Natl Acad Sci U S A. 2009; 106(4):1093-8. PMC: 2633558. DOI: 10.1073/pnas.0808173106. View

13.

Cheng E, Wei M, Weiler S, Flavell R, Mak T, LINDSTEN T . BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001; 8(3):705-11. DOI: 10.1016/s1097-2765(01)00320-3. View

14.

Adams J . The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004; 4(5):349-60. DOI: 10.1038/nrc1361. View

15.

Wei M, Zong W, Cheng E, LINDSTEN T, Panoutsakopoulou V, Ross A . Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001; 292(5517):727-30. PMC: 3049805. DOI: 10.1126/science.1059108. View

16.

Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S . Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002; 2(3):183-92. DOI: 10.1016/s1535-6108(02)00127-7. View

17.

Takeda S, Chen D, Westergard T, Fisher J, Rubens J, Sasagawa S . Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev. 2006; 20(17):2397-409. PMC: 1560414. DOI: 10.1101/gad.1449406. View

18.

Hsieh J, Cheng E, Korsmeyer S . Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell. 2003; 115(3):293-303. DOI: 10.1016/s0092-8674(03)00816-x. View

19.

Khan J, Dunn B, Tong L . Crystal structure of human Taspase1, a crucial protease regulating the function of MLL. Structure. 2005; 13(10):1443-52. DOI: 10.1016/j.str.2005.07.006. View

20.

Maurer U, Charvet C, Wagman A, Dejardin E, Green D . Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell. 2006; 21(6):749-60. DOI: 10.1016/j.molcel.2006.02.009. View